0001654954-23-001633.txt : 20230214 0001654954-23-001633.hdr.sgml : 20230214 20230214065904 ACCESSION NUMBER: 0001654954-23-001633 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230214 FILED AS OF DATE: 20230214 DATE AS OF CHANGE: 20230214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GSK PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15170 FILM NUMBER: 23622199 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS FORMER COMPANY: FORMER CONFORMED NAME: GLAXOSMITHKLINE PLC DATE OF NAME CHANGE: 20010105 6-K 1 a7925p.htm DIRECTOR/PDMR SHAREHOLDING a7925p
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February 2023
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
 
GSK plc (the 'Company')
 
Deferred Annual Bonus Plan Awards
 
On 9 February 2023, the Company granted awards to the Persons Discharging Managerial Responsibilities ('PDMRs') listed below. The awards have been granted in accordance with the rules of the GlaxoSmithKline 2017 Deferred Annual Bonus Plan ('DABP') which was approved by shareholders on 4 May 2017.
 
Executive Directors and other members of the GSK Leadership Team are required to defer part of any bonus earned into Ordinary Shares or American Depositary Shares ('ADSs') for three years. Under the terms of the Remuneration Policy approved by shareholders in 2022, Executive Directors are required to defer 50% of bonus equivalent of the first 200% of salary with any portion in excess of 200% being deferred in full.  Other members of the GSK Leadership Team are required to defer 25% of bonus equivalent of the first 170% of salary into Ordinary Shares or ADSs with any portion in excess of 170% being deferred in full.
 
The awards have been granted as restricted awards over ADSs for US participants and as nil-cost options over Ordinary Shares for all other participants.
 
The numbers of Ordinary Shares and ADSs shown below are exclusive of dividend reinvestment that will accrue during the deferral period. 
 
 
 
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
125,482
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr I Mackay
b)
Position/status
Chief Financial Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
77,751
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Conrad
b)
Position/status
Chief People Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
22,842
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
22,223
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms S Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
 
13,830
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
Chief Commercial Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
53,528
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms S Ramakrishnan
b)
Position/status
Chief Digital and Technology Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W2044
b)
Nature of the transaction
Deferred Bonus Award of ADSs under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
$36.320
11,145
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
President Corporate Development
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
30,942
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Global Supply Chain
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
24,852
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
16,260
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Waterhouse
b)
Position/status
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
39,600
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr T Wood
b)
Position/status
Chief Scientific Officer
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
b)
Nature of the transaction
Deferred Bonus Award of Ordinary Shares under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
£15.010
18,792
 
 
 
 
 
d)
Aggregated information
N/A (single transaction)
Aggregated volume Price
 
e)
Date of the transaction
2023-02-09
f)
Place of the transaction
 
N/A
 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: February 14, 2023
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc